ChromaDex Corp. (CDXC)

[frankvestor8]

Positive result from this trial could well be a catalyst for the stock. I'm particularly impressed by their designed enrollment of 120 seniors 60-80 years old. This is a group highly likely to benefit from NR/pterostilbene/Basis.

This age group design stands out against:

NR Phase 0 Trial (12 adults age 18-30, AUH/Univ. Copenhagen)
NR Phase 1 Trial (12 adults age 30-55, KGK/ChromaDex)

Of course both were only PK studies. But that, combined with the less favorable age groups, made it inherently less likely to produce exciting result.